ASN Kidney Week 2024: Focus on IgAN
Jonathan Barratt discussed advances in IgA nephropathy treatment with Joel Topf at ASN Kidney Week 2024.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
BAFF and APRIL inhibitor atacicept reduced UPCR, hematuria, and Gd-IgA1 and stabilized eGFR in patients with IgAN.
IgAN was a hot topic at ASN Kidney Week and was the focus of an exhibitor spotlight on pathogenesis and the role of APRIL.
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
C3 plays a key role in the formation of Gd-IgA1-containing IC with a nephritogenic capacity for IgAN.
Clinical improvement does not always reflect pathology, so renal biopsy may be needed to determine IgAN treatment efficacy.
Even when levels are below the current KDIGO threshold, proteinuria in IgAN indicates a risk of kidney failure.
Researchers found evidence that anti-mesangium IgA is involved in the pathogenesis of human IgAN.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
A biopsy registry linked with administrative databases proved to be a practical way of studying IgAN at the population level.
Researchers identified six candidate loci that were significantly associated with IgA nephropathy prognosis.
The largest SnRNA-Seq profiling of IgAN kidney cells to date identified noteworthy cell-specific pathways in IgA nephropathy.
A study examined the impact loin pain has on IgAN patients' quality of life and strategies to manage the pain.
Analysis of single-nucleus data described heterogeneity in IgAN and found pathogenic alterations in the IgAN transcriptome.
A study examined the association between gross hematuria after COVID-19 vaccination and renal prognosis in IgAN patients.
Loss-of-function phenotypic screening with LEAPFROG-powered CRISPR-cas9 is likely to identify therapeutic targets for IgAN.
ARPCs isolated from urine of IgAN patients can form renal spheroids and tubular-like structures without external cytokines.
A study examined the association between circulating inflammatory proteins and disease progression in IgAN.
The phase 2 ENVISION trial examined the effect of sibeprenlimab on patients with IgAN.
Advertisement
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.